Addressing the Roots - CPD Network Association

Skip to main content

Home
About
Microsites
Members
Experts
CMEX Databse
Contact
Login

Home
About
Microsites
Members
Experts
CMEX Databse
Contact
Login

FR
EN

Speaker Content

Virtual Speaker Training
Choose Video

Videos

Select a video

Video 1: Program Overview

Video 2: Consider This Patient, Mihika

Video 3: Stepping Back: What are the roots of type 2 diabetes pathophysiology?

Video 4: Comprehensive Management of T2D - Should We Incorporate Modulation of Adiposopathy as a Treatment Goal?

Video 5: Moving Forward Evolving Pharmacotherapy for Comprehensive T2D Management: Focusing on novel approaches to modulating the incretin pathways
Program Slides

For virtual presentations

View online | Download
Program Slides

For in-person presentations

View online | Download

Program Materials

Program Slides

View online | Download
Program Handout

Download
Program Bibliography

Download

Review Papers

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation (Lingvay et al, Lancet 2022)
Reassessing Human Adipose Tissue (Cypess, NEJM 2022)
Ethnic differences in adiposity and diabetes risk - insights from genetic studies (Yaghootkar et al, J Intern Med 2020)
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm (Abdul-Ghani & Defronzo, Diabetes Care 2017)
How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Samms et al, Trends Endocrinol Metab 2020)
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins' (Skow et al, Diabetes Obes Metab 2016)

Study Publications

Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock et al, Lancet. 2021)
Ethnic differences in adiposity and diabetes risk - insights from genetic studies (Yaghootkar et al, J Intern Med 2020)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Ludvik et al, Lancet 2021)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Del Prato et al, Lancet 2021)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (Dahl et al, JAMA 2022)
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, Jastreboff et al, N Engl J Med 2022)

Guidelines

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update (Diabetes Canada)
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Support
Contact
About
Sitemap
© Copyright 2021 CPD Network Association

Website development: © 2007 - 2020 BrightBean Solutions Inc

cpdisup